Severe digital necrosis in an elderly patient with heterozygous factor V Leiden mutation

被引：2

作者：

Patel, GK

Morris, E

Rashid, MR

Anstey, AV

机构：

[1] Univ Wales Hosp, Dept Dermatol, Cardiff CF14 4XN, S Glam, Wales

[2] Royal Gwent Hosp, Dept Dermatol, Newport NP9 2UB, Shrops, England

[3] Royal Gwent Hosp, Dept Haematol, Newport NP9 2UB, Shrops, England

[4] Royal Gwent Hosp, Dept Pathol, Newport NP9 2UB, Shrops, England

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2000年 / 143卷 / 06期

关键词：

digital necrosis; factor V Leiden; protein C; purpura fulminans;

D O I：

10.1046/j.1365-2133.2000.03906.x

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

We report an 81-year-old female with a heterozygous factor V Leiden mutation who developed purpura fulminans. Digital necrosis, a characteristic clinical feature of purpura fulminans was prominent. Purpura fulminans is more common in children and adult, cases are rare. Of eight reported cases of purpura fulminans resulting from a heterozygous factor V Leiden mutation recorded in the literature, only two were in adults: 40 and 42 years of age, respectively. This is the first report of this condition arising in a patient in her eighties.

引用

页码：1302 / 1305

页数：4

共 50 条

[31] Postoperative stroke in a child with cerebral palsy heterozygous for factor V Leiden
Steiner, M
Hodes, MZ
Shreve, M
Sundberg, S
Edson, JR
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2000, 22 (03) : 262 - 264
[32] Arterial thrombosis in mice with factor V Leiden mutation
Sampram, Ellis S.
Saad, Yasser
Ouriel, Kenneth
VASCULAR, 2008, 16 (01) : 31 - 34
[33] Antiphospholipid antibodies and pregnancy outcomes in women heterozygous for Factor V Leiden
Manuck, Tracy
Branch, D. Ware
Lai, Yinglei
Sibai, Baha
Spong, Catherine Y.
Wendel, George, Jr.
Wenstrom, Katharine
Samuels, Philip
Caritis, Steve N.
Sorokin, Yoram
Miodovnik, Menachem
O'sullivan, Mary J.
Conway, Deborah
Wapner, Ronald J.
JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2010, 85 (02) : 180 - 185
[34] Modification of the ProC® Global assay using dilution of patient plasma in factor V-depleted plasma as a screening assay for factor V Leiden mutation
Quincampoix, JC
Legarff, M
Rittling, C
Andiva, S
Toulon, P
BLOOD COAGULATION & FIBRINOLYSIS, 2001, 12 (07) : 569 - 576
[35] Thrombosis in a patient with combined homozygosity for the factor V Leiden mutation and a mutation in the 3′-untranslated region of the prothrombin gene
Wulf, GM
Van Deerlin, VMD
Leonard, DGB
Bauer, KA
BLOOD COAGULATION & FIBRINOLYSIS, 1999, 10 (02) : 107 - 110
[36] Recurrent central retinal vein occlusion in a young thrombophilic patient with factor V Leiden mutation
Incorvaia, C
Bandello, F
Parmeggiani, F
D'Angelo, S
Costagliola, C
Sebastiani, A
EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2002, 12 (02) : 131 - 134
[37] Clinical and laboratory expression of associated thrombophilic conditions (homozygous/heterozygous factor V Leiden mutation and heterozygous prothrombin variant 20210A) in an Italian family
Simioni, P
Tormene, D
Luni, S
Caldato, M
Girolami, A
BLOOD COAGULATION & FIBRINOLYSIS, 2000, 11 (04) : 379 - 384
[38] Clinical manifestations in thrombotic children with factor V Leiden mutation
Gurgey, A
PEDIATRIC HEMATOLOGY AND ONCOLOGY, 1999, 16 (03) : 233 - 237
[39] Usefulness of factor V Leiden mutation testing in clinical practice
Blinkenberg, Ellen O.
Kristoffersen, Ann-Helen
Sandberg, Sverre
Steen, Vidar M.
Houge, Gunnar
EUROPEAN JOURNAL OF HUMAN GENETICS, 2010, 18 (08) : 862 - 866
[40] Factor V Leiden mutation detection before AstraZeneca vaccine
Hosny, Ahmed S.
Sharkawy, Mohamed, I
ITALIAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 2022, 29 (03): : 97 - 99

← 1 2 3 4 5 →